eli lilly glp 1 agonist Lilly's retatrutide, a GIP/GLP-1/glucagon triple agonist, met Phase 3 endpoints, delivering 28.3% weight loss over 80 weeks in TRIUMPH-1. # EliLilly #Retatrutide #GLP1 #GIP #Glucagon #ObesityTreatment #Phase3 #TRIUMPH1 #WeightLossDrugs blood sugar Management of type 2 Medication:Tirzepatide (GLP-1 + GIP)

eli lilly glp 1 agonist Lilly's retatrutide, a GIP/GLP-1/glucagon triple agonist, met Phase 3 endpoints, delivering 28.3% weight loss over 80 weeks in TRIUMPH-1. # EliLilly #Retatrutide #GLP1 #GIP #Glucagon #ObesityTreatment #Phase3 #TRIUMPH1 #WeightLossDrugs blood sugar Management of type 2 Medication:Tirzepatide (GLP-1 + GIP)

Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists - Goldenberg - 2024 - Obesity Reviews - Wiley Online Library

Glatter wasn’t involved in the study

blood sugar

Medication:Tirzepatide (GLP-1 + GIP)

Moreover, once-weekly dosing improves adherence for many individuals